By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Novartis Pharmaceuticals
Corp. v. Actavis LLC et al.
2:13-cv-01028; filed February
20, 2013 in the District Court of New Jersey

• Plaintiff:  Novartis
Pharmaceuticals Corp.
• Defendants:  Actavis LLC; Apotex,
Inc.; Apotex Corp.; Bedford Laboratories, Inc.; Dr. Reddy's Laboratories, Inc.;
Dr. Reddy's Laboratories Ltd.; Emcure Pharmaceuticals USA, Inc.; Emcure
Pharmaceuticals USA, Inc.; Hospira, Inc.; Pharmaceutics International Inc.;
Pharmaforce, Inc.; Sagent Pharmaceuticals, Inc.; ACS DOBFAR Info S.A.; Strides,
Inc.; Agila Specialities Private Ltd.; Sun Pharmaceuticals Industries, Inc.;
Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.; Sun
Pharmaceutical Industries Ltd.; Teva Parenteral Medicines, Inc.; Wockhardt USA
LLC; Wockhardt Ltd.

Infringement of U.S. Patent
Nos. 8,324,189 ("Use of Zolendronate for the Manufacture of a Medicament
for the Treatment of Bone Metabolism Diseases," issued December 4, 2012),
8,052,987 ("Method of Administering Bisphosphonates," issued November
8, 2011), and 7,932,241 ("Pharmaceutical Products Comprising
Bisphosphonates," issued April 26, 2011) based on defendants' anticipated
launch of a generic version of Novartis' Zometa® (zoledronic acid, used for the
prevention of skeletal-related complications associated with cancer) and
Reclast® (zoledronic acid, used to treat osteoporosis and Paget's
disease).  View the complaint here.

Precision Biosciences Inc. et
al. v. Cellectis S.A. et al.
1:13-cv-00247; filed February
19, 2013 in the District Court of Delaware

• Plaintiffs:  Precision
Biosciences Inc.; Duke University
• Defendants:  Cellectis S.A.;
Cellectis Bioresearch; Cellectis Bioresearch Inc.

Infringement of U.S. Patent
No. 8,377,674 ("Method for Producing Genetically-Modified Cells with
Rationally-Designed Meganucleases with Altered Sequence Specificity,"
issued February 19, 2013) based on Cellectis' manufacture, use, and sale of
certain products, including the cGPS® Custom HepG2 Full Kit DD and the CLS4617
meganuclease targeting the human CCR5 gene. 
View the complaint here.

Bayer Pharma AG v. Warner
Chilcott Co., LLC et al.
2:13-cv-00265; filed February
19, 2013 in the District Court of Nevada

• Plaintiff:  Bayer Pharma AG
• Defendants:  Warner Chilcott
Co., LLC; Warner Chilcott (US), LLC

Infringement of U.S. Patent
No. RE43,916 ("Composition for Contraception," reissued January 8,
2013) based on Warner Chilcott's manufacture and sale of its Loestrin® 24 Fe
(norethindrone acetate and ethinyl estradiol tablets, and ferrous fumarate
tablets, used for oral contraception). 
View the complaint here.

Promega Corp. et al. v.
Life Technologies Corp. et al.
3:13-cv-00119; filed February
19, 2013 in the Western District of Wisconsin

• Plainitffs:  Promega
Corp.; Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.
• Defendants:  Life
Technologies Corp.; Applied Biosystems, LLC

Infringement of U.S. Patent
No. RE37,984 ("Process for Analyzing Length Polymorphism in DNA Regions,"
reissued February 11, 2003) based on defendants' use, manufacture, importation,
sales and offers for sale of a line of small tandem repeat products called
AuthentiFiler.  View the complaint here.

Unimed Pharmaceuticals LLC et
al. v. Perrigo Co. et al.
1:13-cv-00236; filed February
15, 2013 in the District Court of Delaware

• Plaintiffs:  Unimed
Pharmaceuticals LLC; Besins Healthcare Inc.
• Defendants:  Perrigo Co.;
Perrigo Israel Pharmaceuticals Ltd.

Infringement of U.S. Patent
No. 6,503,894 ("Pharmaceutical Composition and Method for Treating
Hypogonadism," issued January 7, 2003) following a Paragraph IV
certification as part of Perrigo's filing of an ANDA to manufacture a generic
version of AbbVie's AndroGel® (testosterone gel, used to treat conditions associated
with a deficiency or absence of endogenous testosterone).  View the complaint here.

Cellerant Therapeutics, Inc.
v. Rea
1:13-cv-00201; filed February
12, 2013 in the Eastern District of Virginia

Review and correction of the
patent term adjustment calculation made by the U.S. Patent and Trademark Office
for U.S. Patent No. 8,252,587 ("Methods of Expanding Myeloid Cell
Populations and Uses Thereof," issued August 28, 2012).  View the complaint here.